These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 3298243)

  • 41. [A case of hemolytic-uremic syndrome associated with urinary infection caused by Escherichia coli producing verotoxin].
    Miédougé M; Watine J; Hacini J; Grimont F
    Ann Biol Clin (Paris); 1999; 57(6):727-9. PubMed ID: 10572225
    [No Abstract]   [Full Text] [Related]  

  • 42. Susceptibility to verotoxin as a function of the cell cycle.
    Pudymaitis A; Lingwood CA
    J Cell Physiol; 1992 Mar; 150(3):632-9. PubMed ID: 1537890
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reconstitution of active recombinant Shiga toxin (Stx)1 from recombinant Stx1-A and Stx1-B subunits independently produced by E. coli clones.
    Nishikawa T; Fujii J; Yoshida S; Yutsudo T
    FEMS Microbiol Lett; 1999 Sep; 178(1):13-8. PubMed ID: 10483717
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide.
    Waddell T; Cohen A; Lingwood CA
    Proc Natl Acad Sci U S A; 1990 Oct; 87(20):7898-901. PubMed ID: 2236008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro assessment of a chemically synthesized Shiga toxin receptor analog attached to chromosorb P (Synsorb Pk) as a specific absorbing agent of Shiga toxin 1 and 2.
    Takeda T; Yoshino K; Adachi E; Sato Y; Yamagata K
    Microbiol Immunol; 1999; 43(4):331-7. PubMed ID: 10385199
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-function analyses of Shiga toxin and the Shiga-like toxins.
    Jackson MP
    Microb Pathog; 1990 Apr; 8(4):235-42. PubMed ID: 2200941
    [No Abstract]   [Full Text] [Related]  

  • 47. A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome.
    Armstrong GD; Rowe PC; Goodyer P; Orrbine E; Klassen TP; Wells G; MacKenzie A; Lior H; Blanchard C; Auclair F
    J Infect Dis; 1995 Apr; 171(4):1042-5. PubMed ID: 7706786
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of verotoxin receptors in pathogenesis.
    Lingwood CA
    Trends Microbiol; 1996 Apr; 4(4):147-53. PubMed ID: 8728608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity.
    Perera LP; Samuel JE; Holmes RK; O'Brien AD
    J Bacteriol; 1991 Feb; 173(3):1151-60. PubMed ID: 1991714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cloning and nucleotide sequence of a variant Shiga-like toxin II gene from Escherichia coli OX3:H21 isolated from a case of sudden infant death syndrome.
    Paton AW; Paton JC; Heuzenroeder MW; Goldwater PN; Manning PA
    Microb Pathog; 1992 Sep; 13(3):225-36. PubMed ID: 1291844
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron.
    Ramotar K; Boyd B; Tyrrell G; Gariepy J; Lingwood C; Brunton J
    Biochem J; 1990 Dec; 272(3):805-11. PubMed ID: 2268304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modification of the glycolipid-binding specificity of vero cytotoxin by polymyxin B and other cyclic amphipathic peptides.
    Head S; Ramotar K; Lingwood C
    Infect Immun; 1990 Jun; 58(6):1532-7. PubMed ID: 2160427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit.
    Bast DJ; Banerjee L; Clark C; Read RJ; Brunton JL
    Mol Microbiol; 1999 Jun; 32(5):953-60. PubMed ID: 10361298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential carbohydrate epitope recognition of globotriaosyl ceramide by verotoxins and a monoclonal antibody.
    Chark D; Nutikka A; Trusevych N; Kuzmina J; Lingwood C
    Eur J Biochem; 2004 Jan; 271(2):405-17. PubMed ID: 14717708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Verotoxin/globotriaosyl ceramide recognition: angiopathy, angiogenesis and antineoplasia.
    Lingwood CA
    Biosci Rep; 1999 Oct; 19(5):345-54. PubMed ID: 10763802
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Universal method for the facile production of glycolipid/lipid matrices for the affinity purification of binding ligands.
    Boulanger J; Huesca M; Arab S; Lingwood CA
    Anal Biochem; 1994 Feb; 217(1):1-6. PubMed ID: 8203724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1.
    Sandvig K; Olsnes S; Brown JE; Petersen OW; van Deurs B
    J Cell Biol; 1989 Apr; 108(4):1331-43. PubMed ID: 2564398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences.
    Armstrong GD; Fodor E; Vanmaele R
    J Infect Dis; 1991 Dec; 164(6):1160-7. PubMed ID: 1659599
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Verotoxins and their glycolipid receptors.
    Lingwood CA
    Adv Lipid Res; 1993; 25():189-211. PubMed ID: 8368148
    [No Abstract]   [Full Text] [Related]  

  • 60. A prospective study of exposure to verotoxin-producing Escherichia coli among Canadian children with haemolytic uraemic syndrome. The CPKDRC co-investigators.
    Rowe PC; Orrbine E; Lior H; Wells GA; McLaine PN
    Epidemiol Infect; 1993 Feb; 110(1):1-7. PubMed ID: 8432313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.